FluoGuide A/S (STO: FLUO)

Market Cap	672.84M
Revenue (ttm)	1.76M
Net Income (ttm)	-49.46M
Shares Out	13.62M
EPS (ttm)	-3.77
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	17,114
Average Volume	14,124
Open	49.05
Previous Close	47.90
Day's Range	44.00 - 51.80
52-Week Range	31.85 - 68.60
Beta	1.15
RSI	65.64
Earnings Date	Feb 27, 2025

About FluoGuide

FluoGuide A/S, a clinical stage biotechnology company, focused on developing drugs for surgical outcomes by making cancer fluorescent in Denmark. Its lead product candidate is FG001, which is in Phase IIa and IIb for the treatment of high-grade glioma; Phase II clinical trial for the treatment of lung cancer, and head and neck cancer. The company also develops FG002, which is in preclinical stage that allows surgeons to differentiate cancer from normal tissue during surgery through a novel uPAR-targeted luminescent technology. It has an agreeme...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2018
• Employees: 8
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: FLUO

Financial Performance

In 2023, FluoGuide's revenue was 423,000, a decrease of -93.50% compared to the previous year's 6.51 million. Losses were -38.38 million, 40.4% more than in 2022.

Financial numbers in DKK